Karin H. Hansen

Sdr. Boulevard 29
Odense, 5000, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial.

Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial.

Journal: Future oncology (London, England)

Published: December 18, 2025

Upfront treatment with osimertinib in lung cancer patients with and without active brain metastases, and the role of ctDNA as a biomarker; a phase II clinical trial (the FIOL study).

Upfront treatment with osimertinib in lung cancer patients with and without active brain metastases, and the role of ctDNA as a biomarker; a phase II clinical trial (the FIOL study).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 10, 2025

Clinical and molecular characteristics of 42 Danish patients with metastatic ALK fusion-positive lung cancer treated with first-line alectinib: A nationwide study.

Clinical and molecular characteristics of 42 Danish patients with metastatic ALK fusion-positive lung cancer treated with first-line alectinib: A nationwide study.

Journal: Cancer treatment and research communications

Published: February 14, 2025

Remote Symptom Monitoring of Patients With Advanced Lung Cancer (The ProWide Study): A Randomized Controlled Trial.

Remote Symptom Monitoring of Patients With Advanced Lung Cancer (The ProWide Study): A Randomized Controlled Trial.

Journal: JCO oncology practice

Published: December 10, 2024

Genomic profiling and expanded use of targeted anticancer drugs in solid cancers with exhausted evidence-based treatment options (PRECODE): study protocol of a prospective, non-randomized, cohort study.

Genomic profiling and expanded use of targeted anticancer drugs in solid cancers with exhausted evidence-based treatment options (PRECODE): study protocol of a prospective, non-randomized, cohort study.

Journal: BMC medical genomics

Published: October 09, 2024

Lung cancer patients with anaplastic lymphoma kinase rearrangement lose affiliation with labor market at diagnosis.

Lung cancer patients with anaplastic lymphoma kinase rearrangement lose affiliation with labor market at diagnosis.

Journal: Lung cancer management

Published: May 31, 2024

Clinical outcomes of ALK+ non-small cell lung cancer in Denmark.

Clinical outcomes of ALK+ non-small cell lung cancer in Denmark.

Journal: Acta oncologica (Stockholm, Sweden)

Published: October 10, 2023

ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.

ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.

Journal: BMC cancer

Published: December 22, 2022

Clinical impact of venous thromboembolism in non-small cell lung cancer patients receiving immunotherapy.

Clinical impact of venous thromboembolism in non-small cell lung cancer patients receiving immunotherapy.

Journal: Thrombosis research

Published: August 02, 2022

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials.

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials.

Journal: JTO clinical and research reports

Published: July 19, 2022

Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis.

Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis.

Journal: Cancers

Published: March 09, 2022

Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study.

Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study.

Journal: Acta oncologica (Stockholm, Sweden)

Published: January 11, 2022

Showing 1-12 of 25

Last Updated: 09/26/2026